Dr. Matthew Hill

It's high affinity. So it has the ability... But the tricky thing with that is... It can out-compete 2-AG, but because it's a lower efficacy agonist than 2-AG, in that sense, it's almost blocking the effects, not amplifying them.

It's high affinity. So it has the ability... But the tricky thing with that is... It can out-compete 2-AG, but because it's a lower efficacy agonist than 2-AG, in that sense, it's almost blocking the effects, not amplifying them.

THC and anandamide, the way I would visualize it is because they seem to have relatively similar affinities and efficacies of the receptor, they might, let's say, dance around. So it would be somewhat interchangeable. The difference there is, and this I think is the big point about what THC does versus endocannabinoids, because

THC and anandamide, the way I would visualize it is because they seem to have relatively similar affinities and efficacies of the receptor, they might, let's say, dance around. So it would be somewhat interchangeable. The difference there is, and this I think is the big point about what THC does versus endocannabinoids, because

THC and anandamide, the way I would visualize it is because they seem to have relatively similar affinities and efficacies of the receptor, they might, let's say, dance around. So it would be somewhat interchangeable. The difference there is, and this I think is the big point about what THC does versus endocannabinoids, because

We know now through the pharmaceutical development of drugs that can boost anandamide levels, which exist. We have inhibitors that prevent their metabolism. We can elevate them. There's no intoxication and no psychoactivity associated with elevating anandamide.

We know now through the pharmaceutical development of drugs that can boost anandamide levels, which exist. We have inhibitors that prevent their metabolism. We can elevate them. There's no intoxication and no psychoactivity associated with elevating anandamide.

We know now through the pharmaceutical development of drugs that can boost anandamide levels, which exist. We have inhibitors that prevent their metabolism. We can elevate them. There's no intoxication and no psychoactivity associated with elevating anandamide.

No psychoactive.

No psychoactive.

No psychoactive.

Yeah, no one can guess.

Yeah, no one can guess.

Yeah, no one can guess.

Well, I mean, it was developed... The first molecule really was developed by Pfizer to look at if it could work on pain. The first trial that was done did not work. It was like a...

Well, I mean, it was developed... The first molecule really was developed by Pfizer to look at if it could work on pain. The first trial that was done did not work. It was like a...

Well, I mean, it was developed... The first molecule really was developed by Pfizer to look at if it could work on pain. The first trial that was done did not work. It was like a...

kind of strange osteoarthritic knee pain trial that was like, even in that trial, the positive control of naproxen barely worked, but because the pha inhibitor, which is, take a step back, pha is the enzyme that chews up anandamide. So the drug that is developed inhibits that enzyme. So you prevent the enzymatic breakdown of anandamide. So we just call them pha inhibitors.

kind of strange osteoarthritic knee pain trial that was like, even in that trial, the positive control of naproxen barely worked, but because the pha inhibitor, which is, take a step back, pha is the enzyme that chews up anandamide. So the drug that is developed inhibits that enzyme. So you prevent the enzymatic breakdown of anandamide. So we just call them pha inhibitors.

kind of strange osteoarthritic knee pain trial that was like, even in that trial, the positive control of naproxen barely worked, but because the pha inhibitor, which is, take a step back, pha is the enzyme that chews up anandamide. So the drug that is developed inhibits that enzyme. So you prevent the enzymatic breakdown of anandamide. So we just call them pha inhibitors.